Depo-Provera birth control shot evaluation in NYC

Depo-Provera CI is a clinician-administered progestin birth control injection given every 13 weeks. Evaluation covers pregnancy certainty, medical eligibility, prior dose timing, bleeding expectations, bone health, the current meningioma warning, and plans for repeat injections.

Quick answer

Depo-Provera CI is a clinician-administered progestin birth control injection given every 13 weeks. Evaluation covers pregnancy certainty, medical eligibility, prior dose timing, bleeding expectations, bone health, the current meningioma warning, and plans for repeat injections.

Eligibility and care boundaries

The visit begins with the clinical question and the records that can change the next step.

Personal goals

Review pregnancy prevention goals, desired duration, privacy, comfort with bleeding changes, and how soon future pregnancy may be desired.

Medical eligibility

Unexplained vaginal bleeding, breast cancer history, clotting or stroke history, liver disease, meningioma history, medicines, and other risks can change the recommendation.

Injection timing

Bring the exact date and formulation of the last dose. A late injection can require pregnancy assessment and temporary backup contraception.

STI protection

Depo-Provera does not prevent HIV or other sexually transmitted infections. Condoms and appropriate testing remain separate decisions.

How care works

Choose the method without pressure

A clinician compares the injection with pills, IUDs, implants, rings, patches, barrier methods, and other appropriate choices.

Confirm pregnancy status and timing

The clinician uses the history, current guidance, testing when needed, and prior injection date to decide whether and when a dose can be given.

Confirm product and clinic readiness

The care team verifies the exact formulation, eligible clinic, inventory, trained staff, coverage, and next-dose recall before promising administration.

Plan the next 13 weeks

The follow-up plan covers bleeding, side effects, warning symptoms, the next injection date, and what to do if the next dose will be late.

Depo-Provera CI is one injectable option with specific long-term tradeoffs

The current Depo-Provera CI label carries a boxed warning about loss of bone mineral density and says use beyond two years is not recommended unless other options are considered inadequate. CDC guidance supports individualized eligibility and access decisions rather than a blanket duration rule.

The December 2025 label added a warning about meningioma reported mainly with repeated, long-term medroxyprogesterone acetate exposure. A history of meningioma and new neurologic symptoms need direct clinical review.

The intramuscular Depo-Provera CI pathway is different from self-administered subcutaneous DMPA. The exact formulation, route, dose schedule, and training must be clear before treatment.

Seek prompt care for severe abdominal, neurologic, clotting, or allergic symptoms

Urgent evaluation is needed for severe lower abdominal pain with possible pregnancy, chest pain, shortness of breath, one-sided swelling, sudden vision change, new severe headache, weakness, seizure, or signs of a serious allergic reaction. Persistent heavy bleeding also needs clinical evaluation.

Insurance and access

Confirm whether counseling, the exact injection formulation, administration, pregnancy testing, and follow-up are billed separately. Coverage and inventory vary, and an estimate is not a guarantee of final patient responsibility.

Clinics available for contraception evaluation and injection coordination

The clinic cards show evaluation access, not confirmed Depo-Provera inventory or administration at every site. Confirm the exact formulation, eligible clinic, and appointment type before arrival.